Omnicell (NASDAQ:OMCL) Downgraded to “Hold” Rating by StockNews.com

Omnicell (NASDAQ:OMCL) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Wednesday.

Several other equities analysts have also commented on OMCL. Craig Hallum increased their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Bank of America reiterated a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Benchmark reiterated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Wells Fargo & Company increased their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. increased their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $52.00.

Omnicell Trading Up 6.6 %

NASDAQ:OMCL traded up $3.01 during mid-day trading on Wednesday, hitting $48.46. The stock had a trading volume of 685,543 shares, compared to its average volume of 539,872. The stock has a 50-day simple moving average of $44.41 and a two-hundred day simple moving average of $37.75. The company has a market capitalization of $2.24 billion, a PE ratio of -124.25, a PEG ratio of 34.92 and a beta of 0.81. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.74.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently modified their holdings of the business. Franklin Resources Inc. grew its position in shares of Omnicell by 49.9% during the third quarter. Franklin Resources Inc. now owns 30,807 shares of the company’s stock worth $1,316,000 after acquiring an additional 10,260 shares during the last quarter. Geode Capital Management LLC grew its position in Omnicell by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after buying an additional 2,877 shares during the last quarter. Pier Capital LLC purchased a new position in Omnicell in the 3rd quarter valued at $5,859,000. SageView Advisory Group LLC purchased a new position in Omnicell in the 3rd quarter valued at $480,000. Finally, ArrowMark Colorado Holdings LLC grew its position in Omnicell by 27.1% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock valued at $49,742,000 after buying an additional 243,353 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.